Pacira Pharmaceuticals (NASDAQ:PCRX) released its quarterly earnings results on Wednesday. The company reported $0.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.46, Bloomberg Earnings reports. The company had revenue of $79.08 million during the quarter, compared to analyst estimates of $79.06 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business posted $0.09 earnings per share.
Pacira Pharmaceuticals (PCRX) traded up $0.10 during trading on Thursday, hitting $31.30. 1,251,400 shares of the stock traded hands, compared to its average volume of 1,050,644. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a 1 year low of $29.35 and a 1 year high of $53.80. The company has a market capitalization of $1,265.78, a P/E ratio of -23.89 and a beta of 1.88.
In other news, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.60% of the company’s stock.
Several research firms recently commented on PCRX. Royal Bank of Canada dropped their price target on Pacira Pharmaceuticals to $44.00 and set an “outperform” rating for the company in a research report on Thursday. HC Wainwright dropped their price target on Pacira Pharmaceuticals to $45.00 and set a “buy” rating for the company in a research report on Thursday. Oppenheimer reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Thursday. Canaccord Genuity reissued a “hold” rating and issued a $32.00 price objective on shares of Pacira Pharmaceuticals in a research note on Friday, February 16th. Finally, Needham & Company LLC downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating and set a $55.00 price objective for the company. in a research note on Friday, February 16th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. Pacira Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $45.35.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3228265/pacira-pharmaceuticals-pcrx-announces-quarterly-earnings-results.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.